Survival benefit of conversion surgery for initially unresectable biliary tract cancer: a systematic review and meta-analysis.

ABSTRACT:

Purpose

Combination of gemcitabine and cisplatin (GemCis) is the current first-line treatment for unresectable biliary tract cancer (UR-BTC), but it confers a median overall survival (OS) of less than one year. This study aimed to evaluate the survival benefit of conversion surgery for initially UR-BTC.

Methods

Eligible studies published between January 2000 and May 2024 were identified via an electronic search of PubMed and Web of Science databases. The primary endpoint was OS.

Results

Included in this study were 96 observational studies involving 466 patients with 231 cases (49.6%) of intrahepatic cholangiocarcinoma, 131 cases of (28.1%) extrahepatic cholangiocarcinoma, and 104 cases (22.3%) of gallbladder cancer. The 90-day mortality rate was 4.3%, and the median s

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC11805778 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature